Clinical trials: Sexually Transmitted Disease (STD)
Human Immunodeficiency Virus
Feasibility of Telerehabilitation in HIV-patients
The aim of this study is to assess the feasibility and the effects of a 6-week telerehabilitation on the three domains of the International Classification of Functioning, Disability and Health in HIV-infected patients under…
- Trial name
- NCT03335176
- Testing
- Endurance ad Resistance Training Exercise
- Volunteers
- 25 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
HIV Infections
FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women
This Phase III, double-blind, randomized, placebo-controlled trial enrolled HIV-negative women from 4 sites in 3 countries (Kenya, Tanzania, South Africa).
- Trial name
- NCT00625404
- Testing
- Truvada
- Where
- 4 sites in Kenya, South Africa and 1 more
- Volunteers
- 2,120 people, healthy volunteers welcome
- Sponsor
- FHI 360
HIV Infections
Intervention for (Those) Recently Informed of Seropositive Status (IRISS)
An intervention designed to increase positive affect in a population newly diagnosed with HIV will be effective at improving affect and HIV-related outcomes such as mental and physical health, coping and coping resources.
- Trial name
- IRISS (NCT00720733)
- Testing
- Skills-Building Intervention, Personal Interview Group
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of California, San Francisco
HIV Infections
Lopinavir/r Monotherapy as Maintenance Therapy After Long Term Viral Suppression
1. Objectives Primary To investigate the possibility of maintaining virological suppression of HIV in infected patients, switching them to LPV/r as the only antiretroviral agent To assess the immunological response in patients…
- Trial name
- NCT00160849
- Testing
- Lopinavir/r
- Where
- 2 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Universidade Federal do Rio de Janeiro
HIV Infections
ATV/Ritonavir Nevirapine Interaction (USPAC)
Open-Label, multiple-dose, drug interaction study to assess the effect of nevirapine on the pharmacokinetics of atazanavir in HIV-infected individuals.
- Trial name
- NCT00162149
- Testing
- Nevirapine, Nevirapine + Atazanavir/Ritonavir, Atazanavir + Ritonavir
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
HIV/AIDS
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
This is a phase 2 study to evaluate the safety and tolerability of combination therapy with Albuvirtide (ABT) and 3BNC117 in virologically suppressed subjects with HIV-1 infection and explore the potential of viral suppression…
- Trial name
- NCT04819347
- Testing
- Albuvirtide, 3BNC117
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Frontier Biotechnologies Inc.
Neoplasms, Squamous Cell, Papillomavirus Infections
Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV
The purpose of this study is to determine whether a model can be created to predict the progression of early anal cancer precursor lesions in HIV using potential predictors such as: HIV treatment history, smoking history, sexual…
- Trial name
- NCT01709448
- Where
- 2 sites in United States
- Volunteers
- 165 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infections
Analysis of Immune Responses to HIV Vaccines
This study will evaluate a test designed to measure immune system responses to HIV and HIV vaccines.
- Trial name
- NCT00068978
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Lymphocyte Infusions for the Treatment of HIV-Infected Patients Failing Anti-HIV Therapy
Some HIV-infected individuals have a white blood cell marker known as HLA-B*57 that appears to help control the progress of the disease; however, not all who have the HLA-B*57 marker are able to control the infection.
- Trial name
- NCT00559416
- Testing
- Cell Transfer
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV Infections
A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection
To evaluate the safety and tolerance of oral zidovudine (AZT) when given over a period of 24 weeks to children between 3 months and 12 years of age.
- Trial name
- NCT00000716
- Testing
- Zidovudine
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes).
- Trial name
- MOTIVATE 1 (NCT00098306)
- Testing
- Maraviroc (UK-427,857), Optimized Background Therapy
- Where
- 22 sites in United States, Canada
- Volunteers
- 601 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems
To determine the maximum long-term dosage of ribavirin (RBV) that is safe and free of serious side effects in patients with AIDS or AIDS related illnesses.
- Trial name
- NCT00001015
- Testing
- Ribavirin
- Where
- 5 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycobacterium Avium-intracellulare Infection, HIV Infections
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS
This study is designed to evaluate the efficacy and safety of clarithromycin given orally at 1 of 3 doses to treat disseminated Mycobacterium avium complex infections (MAC) in patients with AIDS.
- Trial name
- NCT00000644
- Testing
- Clarithromycin
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Universal Coverage of Antiretroviral Treatment in Senegal
Senegal plans a rapid scale up of HIV treatment for all people living with HIV, regardless of cluster of differentiation 4 (CD4) count or viral suppression.
- Trial name
- NCT03880006
- Testing
- Case management
- Where
- 4 sites in Senegal
- Volunteers
- 596 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Neisseria Gonorrheae Infection
Performance, Acceptability, and Usability of a Novel Rapid Lateral Flow Test for Detecting Neisseria Gonorrhoeae in Pregnant and Symptomatic Women Attending Clinics in South Africa.
Previous studies of the Neisseria gonorrhoeae (NG) lateral flow assay (LFA) have shown promising results. In East London, South Africa, the LFA demonstrated a sensitivity of 80% in asymptomatic women.
- Trial name
- GO-SA (NCT07530406)
- Testing
- Novel Lateral Flow Assay for Neisseria gonorrhoeae
- Where
- South Africa
- Volunteers
- 1,239 people, healthy volunteers welcome
- Sponsor
- Foundation for Professional Development (Pty) Ltd
HIV Infection, HIV Infections
Testing an HIV Prevention Intervention for Psychiatric Patients in Brazil
This study will test the effectiveness of a program aimed at reducing behaviors that increase HIV risk among people with severe mental illnesses.
- Trial name
- NCT00881699
- Testing
- HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you, Health Promotion Intervention
- Where
- Brazil
- Volunteers
- 460 people
- Sponsor
- New York State Psychiatric Institute
HIV Infections
Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent
Dolutegravir (DTG), a human immunodeficiency virus (HIV)-1 integrase inhibitor (INI), and Rilpivirine (RPV), a non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI), are each approved in the United States (US), European…
- Trial name
- NCT03984838
- Testing
- JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Cervical Intraepithelial Neoplasia, Cervical Cancer
Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
This study is to evaluate lot-lot consistency of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) .
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT05426148
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®
- Where
- China
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Cervical Carcinoma, Human Papillomavirus Infection
Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia
This trial studies how well a multilevel human papillomavirus (HPV) self-testing intervention works in increasing cervical cancer screening among women in Appalachia.
- Trial name
- NCT04411849
- Testing
- Best Practice, HPV Self-Collection, Informational Intervention
- Where
- 4 sites in United States
- Volunteers
- 802 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
HIV Infections
Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
Most currently approved anti-HIV drugs work by stopping the replication of HIV after it has entered cells. AMD070 (also known as AMD11070) is designed to block HIV from entering cells and may be effective in treating patients who…
- Trial name
- NCT00063804
- Testing
- Ritonavir, AMD070
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.